AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03733522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relative isolation
Description: No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
Study NCT02860286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Study NCT04707729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROX index algorithm
Description: The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
Study NCT04125433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Integrated Care Services
Description: The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
Study NCT01354769 — intervention group
Intervention type: DEVICE
Intervention: CapnoStream20
Description: The monitor used for data gathering is a CapnoStream20-multi parameter monitor
Study NCT02296463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F Vaccine with adjuvant (0.5mL injection)
Study NCT02296463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F Vaccine (0.5mL injection)
Study NCT02296463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine (0.5mL injection)
Study NCT02296463 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A Vaccine (0.5mL injection)
Study NCT02296463 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.5mL injection)
Study NCT00002842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Starting dose of 0.2 mg/kg/day for 14 consecutive days.
Study NCT00002842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
Study NCT00002842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
Study NCT00002842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Chemotherapy given after hepatic resection
Study NCT02504268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT02504268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept Placebo
Study NCT02504268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate Placebo
Study NCT03998020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: scale of severity
Description: assessment of the severity of the sleep disorders by scale
Study NCT03998020 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: Genetical study, serum and sample
Study NCT02936687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-1 Inhibition Placebo
Description: Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
Study NCT00016276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT01005511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grindcare
Description: Active treatment
Study NCT01005511 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Grindcare - inactive
Description: Placebo treatment
Study NCT01313364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G x 1 Needle Autoinjector
Description: All subjects will self-administer 4 IM injections using single-use autoinjectors.
Study NCT01745601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg
Description: Reference product
Study NCT01745601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg
Description: Test product
Study NCT04474119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
Study NCT04474119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KN046 placebo
Description: In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks.
Study NCT02477228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ERCP
Description: ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
Study NCT02477228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Precut ERCP
Description: ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
Study NCT01096043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An infusion of an identically appearing solution of sugar water will be intravenously administered.
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 500mcg
Description: fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
Study NCT01096043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strata 1 CXL-1020
Description: Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
Study NCT01096043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strata 2 CXL-1020
Description: One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
Study NCT00002842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Hepatic resection
Study NCT03022123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PL-doxorubicin and epirubicin
Description: PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
Study NCT03022123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL-doxorubicin and epirubicin
Description: PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
Study NCT00393848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential amino acid supplement
Description: 15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
Study NCT00016276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00016276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00016276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00016276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00016276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
Study NCT00016276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01096043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strata 3 CXL-1020
Description: A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
Study NCT02601066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiological Study and ECG holter monitor
Description: Electrophysiological Study and ECG holter monitor implantation
Study NCT02587624 — intervention group
Intervention type: PROCEDURE
Intervention: catheter ablation
Description: Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
Study NCT01475864 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP with metal stent
Description: ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
Study NCT02746523 — intervention group
Intervention type: OTHER
Intervention: Sensory Organization Test
Description: Balance and proprioception test
Study NCT02746523 — intervention group
Intervention type: GENETIC
Intervention: Biomarkers
Description: Blood, urine, and saliva biomarkers
Study NCT02746523 — intervention group
Intervention type: OTHER
Intervention: Conners' Adult ADHD Rating Scale (CAARS)
Description: Adult ADHD rating scale
Study NCT02746523 — intervention group
Intervention type: OTHER
Intervention: Depression Scale
Description: Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
Study NCT02746523 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment (MoCA)
Study NCT00144755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: prophylactic administration of darbepoetin alfa in experimental arm
Study NCT00144755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: prophylactic administration of darbepoetin alfa in experimental arm
Study NCT01042613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cannulation using Accuvein device
Description: If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
Study NCT01042613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Cannulation method
Description: If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
Study NCT03808935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
Study NCT03808935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
Study NCT03281057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT
Description: CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
Study NCT03984279 — intervention group
Intervention type: OTHER
Intervention: Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control
Description: Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
Study NCT03223142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-modal Precision Ablation
Description: In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
Study NCT04612673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: immune checkpoint inhibitor, 200mg, iv, d1,Q3W
Study NCT04868175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
Study NCT06487520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group watching hot environment image
Description: In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients.
Study NCT06487520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: group watching cold environment image
Description: In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients.
Study NCT04868175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan
Description: Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
Study NCT01670409 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SMART
Description: The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
Study NCT01670409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF
Description: Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
Study NCT02821455 — intervention group
Intervention type: PROCEDURE
Intervention: Lung Surgery with One-Lung Ventilation
Description: A single cohort of patients undergoing one-lung ventilation during lung surgery
Study NCT00779324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 100 mg every morning and noon
Study NCT00779324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo tablet every morning and 12 Noon
Study NCT00799344 — intervention group
Intervention type: DEVICE
Intervention: Catania Stent
Description: coronary stent implantation
Study NCT02219087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Study NCT02219087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
Study NCT00841139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: 100mg o bd
Study NCT00841139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet bd
Study NCT03378102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-gamma-secreting HAdV antigen specific T cells
Description: Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
Study NCT02815163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowerment education
Description: 1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback
Study NCT00220766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Study NCT00220766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose, 5% in Water
Study NCT03367065 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dynamic contrast enhanced computerised tomography
Study NCT02730936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Hernia Repair Device
Description: hernia repair
Study NCT00393848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
Study NCT01758029 — intervention group
Intervention type: DRUG
Intervention: testosterone undecanoate
Description: treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
Study NCT00393848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ketoconazole
Study NCT04226703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic upper airway measurements
Description: Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)
Study NCT02015546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: All subjects will receive Vilazodone at 10, 20 or 40mg.
Study NCT05187234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
Study NCT03313934 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)
Description: The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.